Orexo (ORX.ST) Stock Price

Orexo Price

OMX·CLOSED
15.66SEK+0.58 (+3.77 %)
Market closed

Revenue at Orexo has contracted by 8.2% per year over the past 19 years to 26.00 M SEK. Earnings per share have grown at 94.8% per year over the last 3 years. Orexo's net margin stands at -499.2%, down from -39.6% several years earlier. Analysts set a median price target of 41.31 SEK, implying 163.8% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 9% above its 52-week low.

Orexo stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Orexo over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Orexo stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Orexo's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Orexo Stock Price History
DateOrexo Price
8/13/202615.66 SEK
8/12/202615.08 SEK
8/11/202614.52 SEK
8/10/202614.90 SEK
8/7/202614.68 SEK
8/6/202614.34 SEK
8/5/202614.36 SEK
8/4/202614.46 SEK
7/31/202614.70 SEK
7/30/202614.52 SEK
7/29/202614.36 SEK
7/28/202614.94 SEK
7/27/202615.10 SEK
7/24/202615.24 SEK
7/23/202615.32 SEK
7/22/202615.38 SEK
7/21/202615.60 SEK
7/20/202616.48 SEK
7/17/202618.00 SEK
7/15/202621.50 SEK
7/14/202622.45 SEK
7/13/202623.25 SEK
7/10/202623.20 SEK
7/9/202623.95 SEK
7/8/202623.40 SEK
7/7/202624.20 SEK
7/6/202624.35 SEK
7/3/202624.30 SEK
7/2/202624.30 SEK
7/1/202623.60 SEK
6/30/202624.00 SEK
6/29/202624.40 SEK
6/26/202624.50 SEK
6/25/202623.80 SEK
6/24/202622.55 SEK
6/23/202622.50 SEK
6/22/202620.95 SEK
6/18/202621.00 SEK
6/17/202621.00 SEK
6/16/202621.20 SEK
6/15/202620.60 SEK
6/12/202620.70 SEK
6/11/202619.72 SEK
6/10/202619.44 SEK
6/9/202619.70 SEK
6/8/202618.92 SEK
6/5/202618.98 SEK
6/4/202619.42 SEK
6/3/202619.42 SEK
6/2/202619.60 SEK
6/1/202620.10 SEK
5/29/202620.50 SEK
5/28/202621.20 SEK
5/27/202621.70 SEK
5/26/202621.00 SEK
5/25/202619.82 SEK
5/22/202619.92 SEK
5/21/202619.92 SEK
5/20/202619.14 SEK
5/19/202618.80 SEK
5/18/202618.42 SEK
5/15/202618.48 SEK
5/13/202618.60 SEK
5/12/202618.56 SEK
5/11/202618.50 SEK
5/8/202618.48 SEK
5/7/202618.10 SEK
5/6/202618.00 SEK
5/5/202619.48 SEK
5/4/202618.60 SEK
4/30/202618.86 SEK
4/29/202618.92 SEK
4/28/202619.30 SEK
4/27/202619.92 SEK
4/24/202620.20 SEK
4/23/202620.00 SEK
4/22/202620.45 SEK
4/21/202621.40 SEK
4/20/202620.50 SEK
4/17/202621.00 SEK
4/16/202620.45 SEK
4/15/202620.00 SEK
4/14/202620.30 SEK
4/13/202620.35 SEK
4/10/202620.95 SEK
4/9/202620.75 SEK
4/8/202620.70 SEK
4/7/202620.30 SEK
4/2/202622.25 SEK
4/1/202621.85 SEK
3/31/202621.85 SEK
3/30/202621.60 SEK
3/27/202622.35 SEK
3/26/202622.15 SEK
3/25/202622.45 SEK
3/24/202621.80 SEK
3/23/202622.45 SEK
3/20/202622.25 SEK
3/19/202622.75 SEK
3/18/202623.30 SEK
3/17/202623.75 SEK
3/16/202623.35 SEK
3/13/202623.85 SEK
3/12/202624.00 SEK
3/11/202624.00 SEK
3/10/202624.50 SEK
3/9/202625.00 SEK
3/6/202625.40 SEK
3/5/202625.95 SEK
3/4/202626.50 SEK
3/3/202626.45 SEK
3/2/202626.85 SEK
2/27/202628.20 SEK
2/26/202626.50 SEK
2/25/202625.95 SEK
2/24/202626.25 SEK
2/23/202627.00 SEK
2/20/202626.90 SEK
2/19/202626.15 SEK
2/18/202626.30 SEK
2/17/202626.00 SEK
2/16/202627.60 SEK
2/13/202627.10 SEK
2/12/202627.90 SEK
2/11/202628.10 SEK
2/10/202629.80 SEK
2/9/202629.80 SEK
2/6/202628.30 SEK
2/5/202627.20 SEK
2/4/202629.35 SEK
2/3/202629.35 SEK
2/2/202629.80 SEK
1/30/202629.95 SEK
1/29/202630.05 SEK
1/28/202630.30 SEK
1/27/202631.50 SEK
1/26/202632.20 SEK
1/23/202632.15 SEK
1/22/202630.80 SEK
1/21/202630.40 SEK
1/20/202630.45 SEK
1/19/202629.85 SEK
1/16/202631.05 SEK
1/15/202632.35 SEK
1/14/202632.05 SEK
1/13/202633.55 SEK
1/12/202634.40 SEK
1/9/202634.55 SEK
1/8/202635.45 SEK
1/7/202634.40 SEK
1/5/202635.75 SEK
1/2/202632.45 SEK
12/30/202530.10 SEK
12/29/202528.00 SEK
12/23/202527.30 SEK
12/22/202524.00 SEK
12/19/202523.55 SEK
12/18/202523.45 SEK
12/17/202523.25 SEK
12/16/202524.40 SEK
12/15/202525.15 SEK
12/12/202525.00 SEK
12/11/202524.50 SEK
12/10/202524.30 SEK
12/9/202524.40 SEK
12/8/202524.70 SEK
12/5/202525.00 SEK
12/4/202524.70 SEK
12/3/202525.45 SEK
12/2/202525.95 SEK
12/1/202526.40 SEK
11/28/202525.80 SEK
11/27/202525.90 SEK
11/26/202526.75 SEK
11/25/202526.50 SEK
11/24/202526.80 SEK
11/21/202526.50 SEK
11/20/202527.10 SEK
11/19/202527.10 SEK
11/18/202527.05 SEK
11/17/202528.10 SEK
11/14/202528.05 SEK
11/13/202528.80 SEK
11/12/202527.95 SEK
11/11/202528.45 SEK
11/10/202528.75 SEK
11/7/202527.45 SEK
11/6/202526.45 SEK
11/5/202527.35 SEK
11/4/202527.00 SEK
11/3/202527.45 SEK
10/31/202527.80 SEK
10/30/202528.30 SEK
10/29/202528.50 SEK
10/28/202526.80 SEK
10/27/202528.50 SEK
10/24/202528.00 SEK
10/23/202529.95 SEK
10/22/202537.50 SEK
10/21/202538.45 SEK
10/20/202539.60 SEK
10/17/202539.15 SEK
10/16/202538.20 SEK
10/15/202538.00 SEK
10/14/202540.80 SEK
10/13/202541.60 SEK
10/10/202540.90 SEK
10/9/202541.00 SEK
10/8/202539.35 SEK
10/7/202539.45 SEK
10/6/202536.15 SEK
10/3/202538.70 SEK
10/2/202535.00 SEK
10/1/202532.90 SEK
9/30/202533.10 SEK
9/29/202530.35 SEK
9/26/202528.45 SEK
9/25/202529.50 SEK
9/24/202530.15 SEK
9/23/202529.10 SEK
9/22/202528.40 SEK
9/19/202528.95 SEK
9/18/202528.10 SEK
9/17/202526.80 SEK
9/16/202527.80 SEK
9/15/202526.45 SEK
9/12/202525.30 SEK
9/11/202523.60 SEK
9/10/202524.80 SEK
9/9/202524.80 SEK
9/8/202524.80 SEK
9/5/202523.35 SEK
9/4/202520.10 SEK
9/3/202520.10 SEK
9/2/202520.00 SEK
9/1/202521.15 SEK
8/29/202520.90 SEK
8/28/202520.85 SEK
8/27/202521.00 SEK
8/26/202520.45 SEK
8/25/202520.80 SEK
8/22/202520.80 SEK
8/21/202521.20 SEK
8/20/202520.95 SEK
8/19/202521.00 SEK
8/18/202520.45 SEK
8/15/202520.50 SEK
Access this data via the Eulerpool API
Get Free API Key

Orexo Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
565.00 M SEK
-194.30 M SEK
-223.50 M SEK
Jan 1, 2022
624.30 M SEK
-183.90 M SEK
-177.60 M SEK
Jan 1, 2023
638.80 M SEK
-99.10 M SEK
-128.30 M SEK
Jan 1, 2024
590.00 M SEK
-140.30 M SEK
-203.00 M SEK
Jan 1, 2025
26.00 M SEK
-352.90 M SEK
-129.80 M SEK
Jan 1, 2026 (e)
19.00 M SEK
-7.41 M SEK
-338.64 M SEK
Jan 1, 2027 (e)
27.00 M SEK
-10.52 M SEK
-252.08 M SEK
Jan 1, 2028 (e)
33.00 M SEK
-12.86 M SEK
-269.39 M SEK

Orexo Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 14, 2026, 2:49 PM
 
REVENUEM SEK
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM SEK
EBITM SEK
EBIT MARGIN%
NET INCOMEM SEK
NET INCOME GROWTH%
SHARESM
20132014201520162017201820192020202120222023202420252026e2027e2028e
429.00570.00643.00705.00643.00783.00844.00663.00565.00624.00638.00590.0026.0019.0027.0033.00
31.6032.8712.819.64-8.7921.777.79-21.45-14.7810.442.24-7.52-95.59-26.9242.1122.22
93.2481.0578.8578.8774.4978.0387.5690.2086.0288.4686.0587.63-211.54-211.54-211.54-211.54
400.00462.00507.00556.00479.00611.00739.00598.00486.00552.00549.00517.00-55.00-40.19-57.12-69.81
-139.00-25.00-168.0051.0057.0095.00231.00-25.00-194.00-183.00-99.00-140.00-352.00-7.00-10.00-12.00
-32.40-4.39-26.137.238.8612.1327.37-3.77-34.34-29.33-15.52-23.73-1,353.85-36.84-37.04-36.36
-154.00-56.00-197.0029.0023.00137.00219.00-84.00-223.00-177.00-128.00-203.00-129.00-338.00-252.00-269.00
81.18-63.64251.79-114.72-20.69495.6559.85-138.36165.48-20.63-27.6858.59-36.45162.02-25.446.75
32.7735.2334.8734.5834.6735.2235.3434.2934.2034.3734.4534.4834.7134.7134.7134.71
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Orexo generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Orexo retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Orexo's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Orexo has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Orexo's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Orexo stock margins

The Orexo margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Orexo. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Orexo.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
86.04 %
-34.39 %
-39.56 %
Jan 1, 2022
88.42 %
-29.46 %
-28.45 %
Jan 1, 2023
86.08 %
-15.51 %
-20.08 %
Jan 1, 2024
87.78 %
-23.78 %
-34.41 %
Jan 1, 2025
-213.46 %
-1,357.31 %
-499.23 %
Jan 1, 2026 (e)
-213.46 %
-38.98 %
-1,782.33 %
Jan 1, 2027 (e)
-213.46 %
-38.98 %
-933.62 %
Jan 1, 2028 (e)
-213.46 %
-38.98 %
-816.33 %

Orexo Stock Revenue, EBIT, Earnings per Share

The Orexo earnings per share therefore indicates how much revenue Orexo has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
16.52 SEK
-5.68 SEK
-6.53 SEK
Jan 1, 2022
18.17 SEK
-5.35 SEK
-5.17 SEK
Jan 1, 2023
18.54 SEK
-2.88 SEK
-3.72 SEK
Jan 1, 2024
17.11 SEK
-4.07 SEK
-5.89 SEK
Jan 1, 2025
0.75 SEK
-10.17 SEK
-3.74 SEK
Jan 1, 2026 (e)
0.55 SEK
-0.21 SEK
-9.78 SEK
Jan 1, 2027 (e)
0.78 SEK
-0.30 SEK
-7.28 SEK
Jan 1, 2028 (e)
0.95 SEK
-0.37 SEK
-7.78 SEK

Orexo business model & stock analysis

Orexo AB is a Swedish pharmaceutical company that was founded in 1995 and is headquartered in Uppsala. The company focuses on the development of medications for the treatment of pain and addiction disorders. Business model: Orexo's business model is based on the development of innovative medications and their marketing in the global market. The company specializes in the development of medications based on opioid technology. Divisions: Orexo operates in two main business areas: Pharmaceuticals and digital therapeutics. Pharmaceuticals: In the pharmaceutical division, Orexo is primarily involved in the development of medications used in the treatment of pain and addiction disorders. Some of the best-known medications include: - Zubsolv: a medication for the treatment of opioid addiction - Abstral: a fast-acting pain medication for cancer patients - Edluar: a sleep medication for the treatment of sleep disorders Orexo's pharmaceuticals are distributed in over 60 countries worldwide and have already helped many patients alleviate their symptoms. Digital therapeutics: Orexo has expanded its business model and offers digital therapeutics - apps that contribute to improving the success of pain and addiction disorder treatment. One example is the app "Orexo Digital," which helps patients better monitor their medication and document the progress of their treatment. The app is free and can be downloaded by patients who have been prescribed medications from Orexo. History: Orexo was founded in 1995 by a team of researchers from Uppsala University. The company initially focused on the development of medications for the treatment of inflammatory diseases and allergies. In 2003, the company decided to concentrate on the development of medications in pain and addiction treatment. The first products in this area were the pain medication Abstral and the substitution medication Zubsolv. In the following years, the company grew rapidly and opened additional locations in the United States, United Kingdom, and France. Orexo works closely with key players in the healthcare sector to ensure that its medications are accessible to patients worldwide. Products: Abstral: a medication for the treatment of acute and chronic severe pain. It is taken sublingually and acts quickly. Zubsolv: a medication for the treatment of opioid addiction. It contains the active ingredients buprenorphine and naloxone and can alleviate withdrawal symptoms in opioid addiction. Edluar: a sleep medication for the treatment of sleep disorders. It contains the active ingredient zolpidem and is taken sublingually. Orexo Digital: an app to support patients in the treatment of pain and addiction disorders. It enables the monitoring of treatment progress and provides helpful advice for improving treatment success. Conclusion: Orexo is an innovative pharmaceutical company specializing in the development of medications for the treatment of pain and addiction disorders. The company has made a name for itself with its unique opioid technology and offers successful products such as Abstral and Zubsolv. With its expansion into the field of digital therapeutics, Orexo also demonstrates that it remains at the forefront of technology and innovation.

Orexo SWOT Analysis

Strengths

1. Strong market position: Orexo AB holds a significant position in the pharmaceutical industry, particularly in the field of medication for the treatment of opioid dependence.

2. Innovative product portfolio: The company offers unique and innovative pharmaceutical products, such as Zubsolv, which have demonstrated effectiveness and are well-received by the market.

3. Strong research and development capabilities: Orexo AB invests heavily in R&D to develop new medications and enhance existing products. This enables the company to stay at the forefront of technological advancements in the industry.

Weaknesses

1. Limited product diversification: Orexo AB heavily relies on a few key products, making it vulnerable to changes in market demand or competition in those specific therapeutic areas.

2. Geographic concentration: The company's revenue is mainly derived from markets in the United States and Europe, leading to potential risks associated with regional economic fluctuations or regulatory changes.

3. Patent expiration: Some of Orexo AB's major products will face patent expiration in the near future, exposing the company to potential competitors and generic alternatives.

Opportunities

1. Expansion into emerging markets: Orexo AB can explore growth opportunities in emerging markets where the demand for opioid dependence treatment and other pharmaceuticals is increasing.

2. Collaborations and strategic partnerships: The company can develop partnerships with other pharmaceutical companies to access new technologies, diversify its product portfolio, and expand its market reach.

3. Increasing focus on mental health: With the growing importance of mental health awareness, Orexo AB can develop and market medications targeting mental health disorders to address this expanding market segment.

Threats

1. Intense competition: The pharmaceutical industry is highly competitive, and Orexo AB faces competition from both large multinational corporations and smaller specialized companies.

2. Stringent regulatory requirements: The industry is subject to strict regulations and compliance standards, which may impose additional costs and delays on product development and commercialization.

3. Market volatility and economic uncertainty: Economic instability, changes in healthcare policies, or unexpected events can adversely impact the demand for pharmaceutical products and the company's financial performance.

Orexo Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Orexo historical P/E ratio, EBIT multiple, and P/S ratio

Orexo annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Orexo shares outstanding

The number of shares of Orexo was 34.71 M in 2025. This indicates how many shares Orexo is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
34.20 M Stocks
Jan 1, 2022
34.37 M Stocks
Jan 1, 2023
34.45 M Stocks
Jan 1, 2024
34.48 M Stocks
Jan 1, 2025
34.71 M Stocks
Jan 1, 2026 (e)
34.71 M Stocks
Jan 1, 2027 (e)
34.71 M Stocks
Jan 1, 2028 (e)
34.71 M Stocks

Current Orexo forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
80.00 % (4)
Hold
20.00 % (1)
Sell
0.00 % (0)
12M Price Target
41.31
Last Price
15.66
Currency
SEK
12M Return Potential
163.79 %
LTM Return
0 %

Orexo Earnings Calls

2025

Orexo Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
4/25/2024-0.31SEK-160.59 MSEK-2024 Q1
1/24/2024-0.39SEK-162.30 MSEK-2023 Q4
7/18/2023-1.14SEK--SEK-2023 Q2
4/27/2023-1.13SEK--SEK-2023 Q1
1/26/2023-2.28SEK-158.39 MSEK-2022 Q4
11/3/2022-1.70SEK-159.01 MSEK-2022 Q3
7/14/2022-1.21SEK-149.29 MSEK-2022 Q2
4/28/2022-0.20SEK-138.75 MSEK-2022 Q1
1/27/2022-1.72SEK-141.90 MSEK-2021 Q4
11/3/2021-1.71SEK-136.89 MSEK-2021 Q3

EESG©

Eulerpool ESG Scorecard© for the Orexo stock

82/100
79
Environment
93
Social
76
Governance
E

Environment

20
Scope 1 - Direct Emissions273
Scope 2 - Indirect emissions from purchased energy73
Scope 3 - Indirect emissions within the value chain1,314
Total CO₂ emissions346
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees54
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Orexo shareholder structure

% Name
27.84955%
Novo Holdings A/S
Novo Holdings A/S
6.53776%
Avanza Bank Holding AB
Avanza Bank Holding AB
5.14247%
ATP
ATP
4.62081%
Walldov (Anders)
Walldov (Anders)
2.69667%
Swedbank Robur Fonder AB
Swedbank Robur Fonder AB
2.45034%
Nordnet Pensionsforsakring AB
Nordnet Pensionsforsakring AB

Orexo Beneficial Ownership Filings (SEC 13D/G)

Free Float
49.5%
Float Shares
-
Shares Outstanding
-

Orexo Executives and Management Board

12 members · avg. age 58 · 25 % women

NS

Mr. Nikolaj Sorensen (53)

President, Chief Executive Officer

7.49 M SEK

Management

FJ

Mr. Fredrik Jaerrsten

Chief Financial Officer, Executive Vice President

–
RD

Mr. Robert Deluca (64)

President of Orexo US Inc

–
CC

Ms. Cecilia Coupland (49)

Senior Vice President, Head - Operations

–
RR

Mr. Robert Roenn (49)

Senior Vice President, Head - Research and Development

–
EK

Mr. Edward Kim

Chief Medical Officer

–

Board of Directors

CR

Ms. Christine Rankin (61)

Independent Director

600,000.00 SEK
SL

Mr. Staffan Lindstrand (62)

Independent Director

550,000.00 SEK
RE

Mr. Robin Evers (55)

Independent Director

450,000.00 SEK
FW

Mr. Fred Wilkinson (69)

Independent Director

400,000.00 SEK
FH

Dr. Friedrich von Bohlen Und Halbach (63)

Independent Chairman of the Board

53,000.00 SEK
LW

Ms. Lena Wange

Investor Relations and Communications Director · since 2015

–

Orexo Supply Chain

Orexo Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
7 companies
#Nameβ 1YTrend
1
Viatris
Supplier·Customer·Pharmaceuticals·US
-0.42
0.66
0.29
0.43
0.61
0.66
0.24
#Nameβ 1YTrend
1
UnitedHealth Group
Customer·Health Care Providers & Services·US
-0.79
0.55
-0.42
-0.61
-0.78
-0.89
-0.37
2
CVS Health
Customer·Health Care Providers & Services·US
-0.47
0.50
0.49
-0.57
-0.76
-0.85
-0.30
3
Accenture A
Supplier·IT Services·IE
-0.62
0.75
0.43
0.83
0.02
-0.77
0.01
4
Cigna
Customer·Health Care Providers & Services·US
-0.45
0.32
-0.56
-0.74
-0.40
-0.61
-0.19
5
Humana
Customer·Health Care Providers & Services·US
-0.63
0.45
-0.38
-0.01
0
-0.47
0.00

Frequently asked questions about Orexo

The business model of Orexo AB revolves around the development and commercialization of innovative pharmaceutical products. Orexo focuses on improving the treatment options for patients suffering from opioid dependence and pain management. The company leverages its expertise in formulation technologies and clinical development to create patented products with unique characteristics. Orexo's flagship product, Zubsolv®, is a leading medication for opioid dependence, providing convenient and effective treatment. Through collaborations and strategic partnerships, Orexo aims to expand its product portfolio and geographical presence, delivering value to patients, healthcare professionals, and stakeholders.

Orexo AB is primarily active in the pharmaceutical industry.

The main competitors of Orexo AB in the market include pharmaceutical companies such as Indivior PLC, Mallinckrodt Pharmaceuticals, and Teva Pharmaceutical Industries Ltd. These companies also operate in the field of addiction medicine and create products and treatments for substance abuse disorders.

Orexo AB is a pharmaceutical company headquartered in Sweden. Founded in 1995, Orexo has a rich history and background in developing innovative treatments for patients with opioid addiction. The company specializes in creating and commercializing unique medications using its proprietary technologies. With a focus on opioid dependence and pain management, Orexo has established itself as a leading player in the pharmaceutical industry. Orexo AB constantly strives to improve patient outcomes and contribute to the overall well-being of individuals dealing with addiction and pain-related issues.

Orexo AB has achieved several significant milestones since its establishment. The company successfully developed and commercialized Zubsolv®, a sublingual treatment for opioid dependence. Orexo AB also received approval for Abstral®, an innovative sublingual rapid-disintegrating tablet for cancer breakthrough pain management. Additionally, the company has secured partnerships and collaborations with multiple pharmaceutical companies, expanding its global reach and product portfolio. Orexo AB's dedication to research and development has led to the successful launch of pharmaceutical products that address unmet medical needs, reinforcing its position as a leading player in the pharmaceutical industry.

Orexo AB is primarily present in several countries and regions worldwide. The company has a significant presence in Europe, including countries like Sweden, Norway, Denmark, and Finland. Additionally, Orexo AB is expanding its footprint in the United States, where it is steadily growing its market presence. With its innovative pharmaceutical solutions and commitment to improving patient outcomes, Orexo AB is dedicated to reaching more regions and markets in the future.

Orexo AB represents values of innovation, integrity, and patient-centricity. As a pharmaceutical company, Orexo is dedicated to developing innovative solutions for the treatment of substance abuse and mental health disorders. The company's corporate philosophy revolves around improving the lives of patients by providing safe and effective medications. Orexo prioritizes ethical conduct, ensuring transparency and adhering to strict regulatory standards. Through its research and development efforts, Orexo aims to address unmet medical needs and make a positive impact on society. With its strong values and commitment to patient well-being, Orexo AB continues to be a trusted name in the pharmaceutical industry.

Analysts currently set an average price target of 41.31 SEK for the Orexo stock (median: 41.31 SEK), implying +163.8 % versus the latest price. The consensus is based on 5 analyst ratings.

Orexo Analyst Price Targets 2026

5 analysts currently rate the Orexo stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Orexo to generate revenue of 19.00 M SEK and earnings per share of -9.76 SEK.

Orexo Analyst Price Targets 2026

Converted at the current exchange rate, the Orexo share trades at 1.42 EUR (15.66 SEK).

The Orexo share (ORX.ST) is listed on 5 stock exchanges, including: Frankfurt (C5G.F), London (0H19.L).

Orexo AB is a pharmaceutical company focused on developing innovative medications for the treatment of opioid dependence, pain management, and other diseases. The company was founded in 1995 and is headquartered in Uppsala, Sweden. Orexo AB's business model is based on various divisions that allow the company to market its products at different levels. These divisions include medications for the treatment of opioid dependence, medications for pain management, benefit assessment and market access services, and research and development efforts. The company aims to provide tailored medications and services to meet the needs of patients and healthcare professionals. With its focus on opioid dependence and pain management, Orexo AB is well-positioned to serve a growing demographic and maintain high standards of product safety and quality. The company has a strong history of growth and continues to invest in research and development, making it a significant player in the market for opioid dependence and pain management.

The expected revenue of Orexo is 19.00 M SEK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Orexo is -338.64 M SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Orexo is currently -1.60. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Orexo stock.

The price-to-sales ratio (P/S) of Orexo is currently 28.60. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Orexo stock.

The Eulerpool Quality Score for Orexo is 1/10.

The ISIN of Orexo is SE0000736415. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Orexo is A0HG6G. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Orexo is ORX.ST. The ticker symbol is used to trade Orexo shares on the stock exchange.

Orexo paid dividends every year for the past 0 years.

Orexo is assigned to the 'Health' sector.

The dividends of Orexo are distributed in SEK.

All fundamentals and in-depth analysis of Orexo

Our stock analysis for Orexo stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Orexo. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Orexo Stock
Orexo Revenue→
Orexo Stock
Orexo Net Income→
Orexo Stock
Orexo P/E→
Orexo Stock
Orexo P/S→
Orexo Stock
Orexo EBIT→
Orexo Stock
Orexo Dividend→
Orexo Stock
Orexo Directors Dealings→
Orexo Stock
Orexo Stocks→
Orexo Stock
Orexo Market capitalization→
Orexo Stock
Orexo Debt→
Orexo Stock
Orexo Liabilities→
Orexo Stock
Orexo Equity→
Orexo Stock
Orexo AAQS→
Orexo Stock
Orexo Employees→
Orexo Stock
Orexo ROE→
Orexo Stock
Orexo ROA→
Orexo Stock
Orexo ROCE→
Orexo Stock
Orexo News→
Orexo Stock
Orexo Analyst Price Targets→

Health Stocks

Organigram GlobalOrchid PharmaOrganiGram HoldingsOrchestra Biomed HoldingsOrganogenesis HoldingsOraSure TechnologiesOrganon &Oramed PharmaceuticalsOrgenesisOragenicsOric PharmaceuticalsOpus GeneticsAll Stocks A–Z →